This study provides insights into the potential therapeutic impact of targeting FGF signaling in overcoming resistance to CDK4/6 inhibitors and ET in ER+ breast cancer, as further explored in the ongoing Phase 1 clinical trial of tasurgratinib in combination with endocrine therapies (NCT04572295) [21]. The gene discussed is CDK4; the disease is breast cancer.